株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Galectin Therapeutics, Inc.:製品パイプライン分析

Galectin Therapeutics, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256009
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Galectin Therapeutics, Inc.:製品パイプライン分析 Galectin Therapeutics, Inc. - Product Pipeline Review - 2015
出版日: 2015年08月26日 ページ情報: 英文 43 Pages
概要

Galectin Therapeutics, Inc. は、線維症および癌の治療薬の開発と商品化に取り組んでいるバイオテクノロジー企業です。同社はまたガレクチンタンパク質の研究にも力を入れており、臨床試験を行っています。

当レポートでは、Galectin Therapeutics, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Galectin Therapeutics, Inc.の基本情報

Galectin Therapeutics, Inc.の概要

  • 主要情報
  • 企業情報

Galectin Therapeutics, Inc.:R&Dの概要

  • 主な治療範囲

Galectin Therapeutics, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Galectin Therapeutics, Inc.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Galectin Therapeutics, Inc.:薬剤プロファイル

  • GR-MD-02
  • GM-CT-01
  • GM-CT-02
  • GR-MD-01
  • GR-MD-03
  • GR-MD-04
  • Polysaccharides to Inhibit Galectin for Fibrosis, Inflammation and Cancer

Galectin Therapeutics, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Galectin Therapeutics, Inc.:最近のパイプライン動向

Galectin Therapeutics, Inc.:休止中のプロジェクト

Galectin Therapeutics, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • GM-CT-01

Galectin Therapeutics, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07442CDB

Summary

Global Markets Direct's, 'Galectin Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Galectin Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galectin Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Galectin Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Galectin Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Galectin Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Galectin Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Galectin Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Galectin Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Galectin Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galectin Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Galectin Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Galectin Therapeutics, Inc. Snapshot
    • Galectin Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Galectin Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Galectin Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Galectin Therapeutics, Inc. - Pipeline Products Glance
    • Galectin Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Galectin Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Galectin Therapeutics, Inc. - Drug Profiles
    • GR-MD-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-CT-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-CT-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GR-MD-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-CT-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GR-MD-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GR-MD-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Galectin Therapeutics, Inc. - Pipeline Analysis
    • Galectin Therapeutics, Inc. - Pipeline Products by Target
    • Galectin Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Galectin Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Galectin Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Galectin Therapeutics, Inc. - Recent Pipeline Updates
  • Galectin Therapeutics, Inc. - Dormant Projects
  • Galectin Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • GM-CT-01
  • Galectin Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Galectin Therapeutics, Inc., Key Information
  • Galectin Therapeutics, Inc., Key Facts
  • Galectin Therapeutics, Inc. - Pipeline by Indication, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Galectin Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Galectin Therapeutics, Inc. - Phase II, 2015
  • Galectin Therapeutics, Inc. - Phase I, 2015
  • Galectin Therapeutics, Inc. - Preclinical, 2015
  • Galectin Therapeutics, Inc. - Discovery, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Target, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Galectin Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Galectin Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Galectin Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Galectin Therapeutics, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Galectin Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Galectin Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Galectin Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top